16 -2 (34) 2021 — Saidova M. M., Khamroeva Y. S. — SYSTEMIC LESIONS IN SCLERODERMIA

SYSTEMIC LESIONS IN SCLERODERMIA

Saidova M. M., Bukhara State Medical Institute

Khamroeva Y. S. Bukhara State Medical Institute

Resume

Systemic scleroderma (SSD) is an autoimmune disease, which is based on generalized microangiopathy and activation of the processes fibrosis of the skin and internal organs. Most patients develop visceral complications, which usually cause death. SSD are often diagnosed late, when pathological changes in organs are irreversible, and treatment is less effective. At the same time, the results of a large study showed that the mortality rate of patients with SSD reaches 68 per 1000 people per year. So, timely diagnosis of SSD is a difficult, but very important task for a doctor.

Keywords: Systemic scleroderma, diagnosis, Raynaud’s syndrome, sclerodactyly.

First page

77

Last page

83

For citation: Saidova M.M., Khamroeva Y.S. Systemic lesions in sclerodermia//New Day in Medicine 2(34)2021 77-83 https://cutt.ly/0bkGXkA

LIST OF REFERENCES

  1. Ananyeva L.P. New classification criteria for systemic scleroderma (lecture). Scientific and practical rheumatology 2013; 51 (5): 539-44.
  2. Bogdanov A.P., Moiseev S.V. Heart damage in systemic scleroderma: clinical aspects and modern diagnostic methods. Therapeutic Archives 1994; 66 (5): 87-91.
  3. Gadaev A.G., Ichki kasalliklar (a guide for doctors) Toshkent 2013, 757.
  4. Sosnovskaya AV, Fomin VV, Popova EN, et al. Gastroesophageal reflux disease and the relationship with the severity of lung damage in systemic scleroderma. Clinical Nephrology 2016; 1: 24-8.
  5. Starovoitova M.N., Desinova O.V., Koneva O.A. Autoantibody profile in systemic scleroderma. Scientific and Practical Rheumatology 2016; 54 (4): 418-23.
  6. Teplova L.V., Ananyeva L.P., Lesnyak V.N. et al. Systemic scleroderma with interstitial lung disease: comparative clinical characteristics with patients without pulmonary involvement. Scientific and practical rheumatology 2010; 3: 36-41.Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010;22(2):133-8.
  7. Akesson A., Hesselstrand R., Scheja A., et al. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis 2004;63(7):791-6.
  8. Al-Dhaher F.F., Pope J.E.,Ouimet J.M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39(4):269-77.
  9. Aringer M., Muller-Ladner U., Burkhardt H., et al. [Common German language nomenclature for systemic sclerosis]. Z Rheumatol 2015;74(2):100-3.
  10. Barnes J., Mayes M.D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012;24(2):165-70.
  11. Bellando-Randone S., Matucci-Cerinic M.. From Raynaud’s phenomenon to very early diagnosis of systemic sclerosis The VEDOSS approach. Curr Rheumatol Rev 2013;9(4):245-8.
  12. Brown K.M., Middaugh S.J., Haythornthwaite J.A., et al. The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud’s attacks: the Raynaud’s Treatment Study. J Behav Med 2001;24(2):137-53.
  13. Bussone G., Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10(5):248-55.
  14. Cutolo M., Herrick A.L., Distler O., et al. Nail fold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: A multicenter, prospective cohort study. Arthritis Rheumatol 2016;68(10):2527-39.
  15. Derk C.T., Huaman G., Littlejohn J., et al. Predictors of early mortality in systemic sclerosis: a case-control study comparing early versus late mortality in systemic sclerosis. Rheumatol Int 2012;32(12):3841-4.
  16. Diab S., Dostrovsky N., Hudson M., et al. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol 2014;41(11):2179-85.
  17. Galie N., Humbert M., Vachiery J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37(1):67-119.
  18. Hinchcliff M., Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. //Am Fam Physician 2008;78(8):961-8.
  19. Hoogen F.H., Boerbooms A.M., Swaak A.J., et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35(4):364-72.
  20. Hudson M., Thombs B., Baron M., et al. Time to diagnosis in systemic sclerosis: is sex a factor? Arthritis Rheum 2009;61(2):274-8.

file

download